ConductScience.org, home

Paper28828166

Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes.

Kumar J and 2 others. Int J Organ Transplant Med, 2017. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes. Papers, record 28828166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28828166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes.
PubMed
Journal
Int J Organ Transplant Med
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.04
iCite
Revised in PubMed
2020-09-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kumar JJ
2Reccia II
3Kusano TT

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117523697Calcineurin inhibitors in pediatric renal transplant recipients.Paediatr Drugs2007https://conductscience.org/library/papers/17523697PubMed
223415313Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.J Heart Lung Transplant2013https://conductscience.org/library/papers/23415313PubMed
324266969Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.Am J Transplant2013https://conductscience.org/library/papers/24266969PubMed
424004351Growing experience with mTOR inhibitors in pediatric solid organ transplantation.Pediatr Transplant2013https://conductscience.org/library/papers/24004351PubMed
519295318
Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Transplantation2009https://conductscience.org/library/papers/19295318PubMed
620155724mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?J Nephrol2010https://conductscience.org/library/papers/20155724PubMed
723909498Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.Clin Transplant2013https://conductscience.org/library/papers/23909498PubMed
821136903Urinary proteomic analysis of chronic allograft nephropathy.Proteomics Clin Appl2008https://conductscience.org/library/papers/21136903PubMed
915446315Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.Transplantation2004https://conductscience.org/library/papers/15446315PubMed
1024175203Is it time to give up with calcineurin inhibitors in kidney transplantation?World J Transplant2013https://conductscience.org/library/papers/24175203PubMed
1119384179Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.Transplantation2009https://conductscience.org/library/papers/19384179PubMed
1224565231Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Transplant Res2013https://conductscience.org/library/papers/24565231PubMed
1324309084Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?Int J Cardiol2014https://conductscience.org/library/papers/24309084PubMed
1424151517Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.Clin Dev Immunol2013https://conductscience.org/library/papers/24151517PubMed
1519422337Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.Am J Transplant2009https://conductscience.org/library/papers/19422337PubMed
1620463641
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Transplantation2010https://conductscience.org/library/papers/20463641PubMed
1721775930Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.Transplantation2011https://conductscience.org/library/papers/21775930PubMed
1820061999Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.Transplantation2010https://conductscience.org/library/papers/20061999PubMed
1921334736Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.Lancet2011https://conductscience.org/library/papers/21334736PubMed
2021162600Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?Paediatr Drugs2011https://conductscience.org/library/papers/21162600PubMed

See all 33 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
33816147Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review.World J Transplant2021https://conductscience.org/library/papers/33816147

Source PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28828166

GET https://conductscience.org/api/papers/v1/28828166/references?page=2